

Supplementary Material 1. Search Strategy

Search strategy for Web of Science:

Search number	Search strategy	Results
#1	(TS= (juvenile idiopathic arthritis)) AND TS=(guideline) and 1.106.1646 Juvenile Idiopathic Arthritis (Citation Topics Micro)	244
#2	((TS= (juvenile idiopathic arthritis))) AND TI=(quality) and 1.106.1646 Juvenile Idiopathic Arthritis (Citation Topics Micro)	116
#3	#1 OR #2	357


Search strategy for Scopus:

Search number	Search strategy			
#1	((TITLE-ABS-KEY (juvenile AND idiopathic AND arthritis) AND TITLE (quality))) OR ((TITLE-ABS-KEY (juvenile	221		
	AND idiopathic AND arthritis) AND TITLE (guideline)))			

Search strategy for MEDLINE through PubMed:

Search number	Search strategy	Results
#1	"Arthritis, Juvenile"[Mesh]	11,649
#2	("Arthritis, Juvenile"[Mesh]) AND (quality [Title/Abstract])	603
#3	((("Guideline" [Publication Type]) OR "Guidelines as Topic"[Mesh]) OR "Guideline Adherence"[Mesh]) OR "Practice Guideline" [Publication Type]	227,756
#4	("Arthritis, Juvenile"[Mesh]) AND (((("Guideline" [Publication Type]) OR "Guidelines as Topic"[Mesh]) OR "Guideline Adherence"[Mesh]) OR "Practice Guideline" [Publication Type])	101
#5	(("Arthritis, Juvenile"[Mesh]) AND (quality [Title])) OR (("Arthritis, Juvenile"[Mesh]) AND (((("Guideline" [Publication Type]) OR "Guidelines as Topic"[Mesh]) OR "Guideline Adherence"[Mesh]) OR "Practice Guideline" [Publication Type]))	239

Supplementary Material 2. PRISMA flow diagram



REFERENCES

- 1. Davies K, Cleary G, Foster H, Hutchinson E, Baildam E. BSPAR Standards of Care for children and young people with juvenile idiopathic arthritis. Rheumatology (Oxford) 2010;49:1406-8.
- Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, et al. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011;63:10-6.
- 3. Munro J, Murray K, Boros C, Chaitow J, Allen RC, Akikusa J, et al. Australian Paediatric Rheumatology Group standards of care for the management of juvenile idiopathic arthritis. J Paediatr Child Health 2014;50:663-6.
- 4. McErlane F, Foster HE, Armitt G, Bailey K, Cobb J, Davidson JE, et al. Development of a national audit tool for juvenile idiopathic arthritis: a BSPAR project funded by the Health Care Quality Improvement Partnership. Rheumatology (Oxford) 2018;57:140-51.
- Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol 2019;71:846-63.
- 6. Scott C, Chan M, Slamang W, Okong'o L, Petty R, Laxer RM, et al. Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind. Clin Rheumatol 2019;38:563-75.
- 7. Barber CEH, Twilt M, Pham T, Currie GR, Benseler S, Yeung RSM, et al. A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care. Arthritis Res Ther 2020;22:53.
- McErlane F, Armitt G, Cobb J, Bailey K, Cleary G, Douglas S, et al. CAPTURE-JIA: a consensus-derived core dataset to improve clinical care for children and young people with juvenile idiopathic arthritis. Rheumatology (Oxford) 2020;59:137-45.
- 9. Alkwai HM, Mirza A, Abdwani R, Asiri A, Bakry R, Alenazi A, et al. Consensus clinical approach for a newly diagnosed systemic juvenile idiopathic arthritis among members of the pediatric rheumatology Arab group. Int J Pediatr Adolesc Med 2021;8:129-33.
- 10. El Miedany Y, Salah S, Lotfy H, El Gaafary M, Abdulhady H, Salah H, et al. Updated clinical practice treat-to-target guidelines for JIA management: the Egyptian College of Pediatric Rheumatology initiative. Egypt Rheumatol Rehabil 2022;49:27.
- 11. El Tal T, Ryan ME, Feldman BM, Bingham CA, Burnham JM, Batthish M, et al. Consensus approach to a treat-to-target strategy in juvenile idiopathic arthritis care: report from the 2020 PR-COIN consensus conference. J Rheumatol 2022;49:497-503.
- 12. Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: recommendations for nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Arthritis Rheumatol 2022;74:570-85.
- Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2022;74:553-69.
- 14. Oommen PT, Strauss T, Baltruschat K, Foeldvari I, Deuter C, Ganser G, et al. Update of evidence- and consensus-based guidelines for the treatment of juvenile idiopathic arthritis (JIA) by the German Society of Pediatric and Juvenile Rheumatic Diseases (GKJR): new perspectives on interdisciplinary care. Clin Immunol 2022;245:109143.

Supplementary Material 3. Level of evidence for candidate QIs

Quality indicator	Statement	Level of evidence					
Domain 1: Access to care							
QI (1)	IF a patient is referred with possible juvenile idiopathic arthritis (JIA), THEN they should be seen by a pediatric rheumatologist within 4 weeks from the date of referral.	В					
Domain 2: Clinical assessment							
QI (2)	IF a patient has JIA, THEN a parent's or patient's global assessment of disease activity using a valid and reliable age-appropriate tool should be performed at the first visit and repeated at each subsequent visit.	В					
QI (3)	IF a patient has JIA, THEN an assessment of functional ability using a valid and reliable age-appropriate tool should be performed at the first visit and repeated every 6 months.	С					
QI (4)	IF a patient has JIA, THEN a physician's global assessment of disease activity using a valid and reliable age- appropriate tool should be performed at the first visit and repeated at each subsequent visit.	В					
QI (5)	IF a patient has JIA, THEN a full active joint count should be performed at the first visit and repeated at each subsequent visit.	С					
QI (6)	IF a patient has JIA, THEN an assessment of the health-related quality of life using a valid and reliable age- appropriate tool should be performed at the first visit and repeated every 6 months.	В					
QI (7)	IF a patient has JIA, THEN a valid and reliable age-appropriate tool to measure disease activity should guide treatment decisions to facilitate a treat-to-target approach.	В					
QI (8)	IF a patient has JIA, THEN antinuclear antibody (ANA), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), and HLA-B27 should be performed as appropriate at the first visit and repeated for confirmation as indicated.	В					
Domain 3: N	Iedication & medication monitoring						
QI (9)	IF a patient has JIA, THEN medications should be chosen according to published clinical practice guidelines and local availability.	А					
QI (10)	IF a patient with JIA is on non-steroidal anti-inflammatory drugs (NSAIDs), THEN baseline monitoring via complete blood count, liver and renal function tests, and a urinalysis should be performed and repeated every 6 to 12 months.	В					
QI (11)	IF a patient has JIA, THEN screening for tuberculosis should be performed prior to initiating treatment with a biologic DMARD and repeated whenever there is a concern for exposure.	В					
QI (12)	IF a patient with JIA is on methotrexate, THEN folic/folinic acid should be prescribed.	А					
QI (13)	IF a patient with JIA is on methotrexate, sulfasalazine, or leflunomide, THEN baseline monitoring via complete blood count, liver and kidney function tests, and a urinalysis should be performed and repeated every 3~4 months.	В					
QI (14)	IF a patient with JIA is on TNF inhibitors, THEN baseline monitoring via complete blood count and liver function tests should be performed and repeated yearly.	В					
QI (15)	IF a patient with JIA is on tocilizumab, THEN baseline monitoring via complete blood count, and liver and renal function tests should be performed and repeated every 3~4 months with lipid monitoring every 6 months.	В					
QI (16)	IF a patient with JIA is on canakinumab or anakinra, THEN baseline monitoring via complete blood count and liver function test should be performed and repeated every 3~4 months.	В					
QI (17)	IF a patient with JIA is on canakinumab or anakinra, THEN liver function tests should be monitored within the first 1~2 months and repeated every 3~4 months.	В					
QI (18)	IF a patient with JIA is on tofacitinib, THEN baseline monitoring via complete blood count, and liver function test should be performed and repeated every 3~4 months.	В					
QI (19)	IF a patient with JIA is on tofacitinib, THEN baseline monitoring via a lipid panel should be performed 1~2 months after initiating treatment.	В					
QI (20)	IF a patient with JIA is on hydroxychloroquine, THEN baseline retinal screening should be performed and repeated yearly.	В					
QI (21)	IF a patient with JIA is on hydroxychloroquine, THEN baseline monitoring via complete blood count, liver and kidney function test, and a urinalysis should be performed and repeated yearly.	В					
QI (22)	IF a patient has JIA, THEN appropriate imaging studies should be performed as indicated.	В					

Quality indicator	Statement	Level of evidence					
Domain 4: Screening for comorbidities							
QI (23)	IF a patient has JIA, THEN ophthalmic screening for uveitis should be performed according to published clinical practice guidelines.	А					
QI (24)	IF a patient has JIA, THEN monitoring growth (height, weight) should be performed at the first visit and repeated at each subsequent visit.	С					
QI (25)	IF a patient has JIA, THEN screening and monitoring for osteoporosis (particularly if they are on corticosteroid therapy) via bone profile, vitamin D level, and bone density should be part of routine clinical assessment.	С					
QI (26)	IF a patient has JIA, THEN monitoring mental health and well-being should be part of routine clinical assessment.	С					
QI (27)	IF a patient has JIA, THEN referral to other services (physiotherapist, occupational therapist, dietitian, etc.) should be performed as indicated.	С					
Domain 5: C	ounselling						
QI (28)	IF a patient has JIA, THEN the immunization status should be reviewed and optimized at diagnosis and annually thereafter in line with local immunization schedules.	A					
QI (29)	IF a patient with JIA is engaging in high-risk behaviors that are detrimental to their health, THEN counselling should be provided at each visit (if not then annually).	С					
QI (30)	IF a female patient (of childbearing age) has JIA, THEN counselling regarding appropriate contraception while on potentially teratogenic medications is performed at least yearly.	А					
Domain 6: S	elf-efficacy and satisfaction with care						
QI (31)	IF a patient has JIA, THEN an assessment for self-efficacy using a valid and reliable tool should be performed within 6 months of the first visit and then every 6 months.	С					
QI (32)	IF a patient has JIA, THEN an assessment of the satisfaction with care provided should be obtained within a year of the first visit and repeated yearly.	С					

	Agency for healthcare research and quality (AHRQ) level of evidence for practice guidelines
А	There is good research-based evidence to support the recommendation.
В	There is fair research-based evidence to support the recommendation.
С	The recommendation is based on expert opinion and panel consensus.
Х	There is evidence of harm from this intervention.

Supplementary Material 4. QIs rating from the first round

	-	Validity Median	Mean absolute _ deviation	Feasibility Median	_Mean absolute deviation
Doma	in 1: Access to care				
1	IF a patient is referred with possible juvenile idiopathic arthritis (JIA), THEN they should be seen by a pediatric rheumatologist within 4 weeks from the date of referral.	9	0	7.5	0.5
Doma	in 2: Clinical assessment				
2	IF a patient has JIA, THEN a parent's or patient's global assessment of disease activity using a valid and reliable age-appropriate tool should be performed at the first visit and repeated at each subsequent visit.	9	0	7.5	1.5
3	IF a patient has JIA, THEN an assessment of functional ability using a valid and reliable age-appropriate tool should be performed at the first visit and repeated every 6 months.*	9	0	7	1
4	IF a patient has JIA, THEN a physician's global assessment of disease activity using a valid and reliable age-appropriate tool should be performed at the first visit and repeated at each subsequent visit.	9	0	8	1
5	IF a patient has JIA, THEN a full active joint count should be performed at the first visit and repeated at each subsequent visit.	9	0	9	0
6	IF a patient has JIA, THEN an assessment of the health-related quality of life using a valid and reliable age-appropriate tool should be performed at the first visit and repeated every 6 months.*	8	1	6.5	1.5
7	IF a patient has JIA, THEN a valid and reliable age-appropriate tool to measure disease activity should guide treatment decisions to facilitate a treat-to-target approach.	9	0	8	1
8	IF a patient has JIA, THEN antinuclear antibody (ANA), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), and HLA-B27 should be performed as appropriate at the first visit and repeated for confirmation as indicated.*	9	0	7.5	1.5
Doma	in 3: Medication & medication monitoring				
9	IF a patient has JIA, THEN medications should be chosen according to published clinical practice guidelines and local availability.	9	0	9	0
10	IF a patient with JIA is on non-steroidal anti-inflammatory drugs (NSAIDs), THEN baseline monitoring via complete blood count, liver and renal function tests, and a urinalysis should be performed and repeated every 6 to 12 months.**	7.5	1.5	9	0
11	IF a patient has JIA, THEN screening for tuberculosis should be performed prior to initiating treatment with a biologic DMARD and repeated whenever there is a concern for exposure.	9	0	9	0
12	IF a patient with JIA is on methotrexate, THEN folic/folinic acid should be prescribed.	9	0	9	0
13	IF a patient with JIA is on methotrexate, sulfasalazine, or leflunomide, THEN baseline monitoring via complete blood count, liver and kidney function tests, and a urinalysis should be performed and repeated every 3~4 months.	9	0	9	0
14	IF a patient with JIA is on TNF inhibitors, THEN baseline monitoring via complete blood count and liver function tests should be performed and repeated yearly.	9	0	9	0
15	IF a patient with JIA is on tocilizumab, THEN baseline monitoring via complete blood count, and liver and renal function tests should be performed and repeated every 3~4 months with lipid monitoring every 6 months.	9	0	9	0

		Validity	Mean absolute	Feasibility	Mean absolute
		Median	deviation	Median	deviation
16	IF a patient with JIA is on canakinumab or anakinra, THEN baseline monitoring via complete blood count and liver function test should be performed and repeated every 3~4 months.	9	0	9	0
17	IF a patient with JIA is on canakinumab or anakinra, THEN liver function tests should be monitored within the first 1~2 months and repeated every 3~4 months.	9	0	8.5	0.5
18	IF a patient with JIA is on tofacitinib, THEN baseline monitoring via complete blood count, and liver function test should be performed and repeated every 3~4 months.	9	0	9	0
19	IF a patient with JIA is on tofacitinib, THEN baseline monitoring via a lipid panel should be performed 1~2 months after initiating treatment.	8	1	9	0
20	IF a patient with JIA is on hydroxychloroquine, THEN baseline retinal screening should be performed and repeated yearly.	9	0	8	1
21	IF a patient with JIA is on hydroxychloroquine, THEN baseline monitoring via complete blood count, liver and kidney function test, and a urinalysis should be performed and repeated yearly.	8	1	8	1
22	IF a patient has JIA, THEN appropriate imaging studies should be performed as indicated.	9	0	8	1
Doma	in 4: Screening for comorbidities				
23	IF a patient has JIA, THEN ophthalmic screening for uveitis should be performed according to published clinical practice guidelines.	9	0	9	0
24	IF a patient has JIA, THEN monitoring growth (height, weight) should be performed at the first visit and repeated at each subsequent visit.	9	0	9	0
25	IF a patient has JIA, THEN screening and monitoring for osteoporosis (particularly if they are on corticosteroid therapy) via bone profile, vitamin D level, and bone density should be part of routine clinical assessment.*	9	0	8	1
26	IF a patient has JIA, THEN monitoring mental health and well-being should be part of routine clinical assessment.*	9	0	7	1.5
27	IF a patient has JIA, THEN referral to other services (physiotherapist, occupational therapist, dietitian, etc.) should be performed as indicated.*	9	0	7.5	1.5
Doma	in 5: Counselling				
28	IF a patient has JIA, THEN the immunization status should be reviewed and optimized at diagnosis and annually thereafter in line with local immunization schedules.	9	0	9	0
29	IF a patient with JIA is engaging in high-risk behaviors that are detrimental to their health, THEN counselling should be provided at each visit (if not, then annually).*	9	0	7	1
30	IF a female patient (of childbearing age) has JIA, THEN counselling regarding appropriate contraception while on potentially teratogenic medications is performed at least yearly.	9	0	8.5	0.5
Domain 6: Self-efficacy and satisfaction with care					
31	IF a patient has JIA, THEN an assessment for self-efficacy using a valid and reliable tool should be performed within 6 months of the first visit and then every 6 months.*	9	0	6.5	2
32	IF a patient has JIA, THEN an assessment of the satisfaction with care provided should be obtained within a year of the first visit and repeated yearly.	8.5	0.5	7	1
the Difference	reamont on the feasibility of the Ol				

*Disagreement on the feasibility of the QI. **Disagreement on the validity of the QI.

		Validity	Mean absolute	Feasibility	Mean absolute
		Median	deviation	Median	deviation
Doma	in 2: Clinical assessment				
2	IF a patient has JIA, THEN a parent's or patient's global assessment of disease activity using a valid and reliable age- appropriate tool should be performed at the first visit and repeated at each subsequent visit.	8	0	8	1
4	IF a patient has JIA, THEN a physician's global assessment of disease activity using a valid and reliable age-appropriate tool should be performed at the first visit and repeated at each subsequent visit.	9	0	8	1
7	IF a patient has JIA, THEN a valid and reliable age-appropriate tool to measure disease activity should guide treatment decisions to facilitate a treat-to-target approach.	8	0	8	0
Doma	in 3: Medication & medication monitoring				
19	IF a patient with JIA is on tofacitinib, THEN baseline monitoring via a lipid panel should be performed 1~2 months after initiating treatment.	8	1	8	1
20	IF a patient with JIA is on hydroxychloroquine, THEN baseline retinal screening should be performed and repeated yearly.	9	0	9	0
21	IF a patient with JIA is on hydroxychloroquine, THEN baseline monitoring via complete blood count, liver and kidney function test, and a urinalysis should be performed and repeated yearly.	8	1	9	0
22	IF a patient has JIA, THEN appropriate imaging studies should be performed as indicated.	9	0	9	0
Doma	Domain 6: Self-efficacy and satisfaction with care				
32	IF a patient has JIA, THEN an assessment of the satisfaction with care provided should be obtained within a year of the first visit and repeated yearly.	9	0	8	1